
BBOT Stock Forecast & Price Target
BBOT Analyst Ratings
Bulls say
BridgeBio Oncology is supported by a differentiated RAS-focused pipeline with BBO-8520, BBO-10203, and BBO-11818 aimed at high-need cancers, and the company’s strategy of combining ON/OFF inhibition with pembrolizumab or PI3Kα pathway blockade could create meaningful clinical differentiation. Recent data are encouraging, including BBO-8520 showing a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRAS G12C inhibitor-experienced NSCLC, alongside favorable liver safety, while BBO-10203 has shown a strong safety profile that may support combination development. With $315.3 million in cash and investments at 3Q26, runway into 2029, and upcoming 4Q26 and mid-2027 readouts, the company has both financial flexibility and multiple catalysts to further de-risk its portfolio.
Bears say
BridgeBio Oncology is exposed to substantial fundamental risk because all three lead programs—BBO-8520, BBO-10203, and BBO-11818—remain in Ph1 clinical trials, so any weaker-than-expected efficacy, safety, or therapeutic window data could materially undermine future approval prospects and valuation. Although BBO-8520 has shown promising KRAS G12C activity, the move into the 2L+ setting narrows the commercial opportunity versus the more attractive 1L market, while the broader KRASm space is crowded with first-generation and late-stage competitors that could limit market share. Regulatory delay risk and the need to secure favorable reimbursement further pressure the outlook, especially given that the company has no approved products and therefore limited operating leverage or commercial diversification.
This aggregate rating is based on analysts' research of BridgeBio Oncology Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBOT Analyst Forecast & Price Prediction
Start investing in BBOT
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About BridgeBio Oncology Therapeutics Inc (BBOT) Forecast
BBOT Analyst Forecast & Price Prediction
Start investing in BBOT
Order type
Buy in
Order amount
Est. shares
0 shares